Anixa Biosciences, Inc. (NASDAQ:ANIX – Get Free Report) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 627,200 shares, a drop of 8.9% from the September 15th total of 688,800 shares. Based on an average trading volume of 96,300 shares, the days-to-cover ratio is currently 6.5 days. Currently, 2.1% of the company’s shares are sold short.
Anixa Biosciences Stock Performance
Shares of NASDAQ ANIX opened at $3.06 on Thursday. Anixa Biosciences has a fifty-two week low of $2.14 and a fifty-two week high of $5.13. The firm has a market capitalization of $97.94 million, a PE ratio of -8.27 and a beta of 0.86. The stock’s 50-day simple moving average is $3.21 and its 200-day simple moving average is $2.96.
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its quarterly earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. On average, sell-side analysts forecast that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Research Report on ANIX
Insider Activity at Anixa Biosciences
In other news, Director Lewis H. Titterton, Jr. bought 21,646 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was bought at an average cost of $3.06 per share, for a total transaction of $66,236.76. Following the acquisition, the director now directly owns 890,754 shares of the company’s stock, valued at $2,725,707.24. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 22.60% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ANIX. Staley Capital Advisers Inc. acquired a new position in shares of Anixa Biosciences in the first quarter valued at approximately $31,000. Concorde Asset Management LLC purchased a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $31,000. Nations Financial Group Inc. IA ADV boosted its stake in shares of Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares in the last quarter. Finally, Virtu Financial LLC boosted its stake in shares of Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Featured Articles
- Five stocks we like better than Anixa Biosciences
- 5 discounted opportunities for dividend growth investors
- Why Buffett Loves Occidental Stock And What It Means for Chevron
- High Flyers: 3 Natural Gas Stocks for March 2022
- UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
- What does consumer price index measure?
- Why Alphabet Could Rally 30% Before Christmas
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.